Drug-induced liver injury due to nitrofurantoin : Similar clinical features, but different HLA risk alleles in an independent cohort

Funding Information: This study is part of the COST Action “CA17112 - Prospective European Drug-Induced Liver Injury Network”supported by COST (European Cooperation in Science and Technology) (www.cost.eu). The genome-wide association study and iDILIC case enrolment and sample collection was funded by the International Serious Adverse Events Consortium. The University of Nottingham sample collection was funded by the National Institute for Health Research (NIHR) Nottingham Digestive Diseases Biomedical Research Unit at the Nottingham University Hospitals NHS Trust and University of Nottingham. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. GPA is the gastrointestinal and liver disorder theme lead for the NIHR Nottingham BRC (Reference no: BRC-1215-20003). The Spanish DILI Registry is partly funded by the Spanish Medicine Agency, Fondo Europeo de Desarrollo Regional - FEDER (FIS PI19_00883, PI 21_01248). CIBERehd is funded by Instituto de Salud Carlos III. Funding Information: This study is part of the COST Action “CA17112 - Prospective European Drug-Induced Liver Injury Network”supported by COST (European Cooperation in Science and Technology) ( www.cost.eu ). The genome-wide association study and iDILIC case enrolment and sample collection was funded by the International Serious Adverse Events Consortium . The University of Nottingham sample collection was funded by the National Institute for Health Research (NIHR) Nottingham Digestive Diseases Biomedical Research Unit at the Nottingham University Hospitals NHS Trust and University of Nottingham. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. GPA is the gastrointestinal and liver disorder theme lead for the NIHR Nottingham BRC (Reference no: BRC-1215-20003). The Spanish DILI Registry is partly funded by the Spanish Medicine Agency , Fondo Europeo de Desarrollo Regional - FEDER ( FIS PI19_00883 , PI 21_01248 ). CIBERehd is funded by Instituto de Salud Carlos III .Peer reviewe